Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 confidence interval 0.59-0.87; P=18F labeled fluorodeoxyglucose metabolic activity in lymphomatous lesions. These results suggest an operationally practical 5-point scale workflow paradigm for potential use in larger clinical trials evaluating lymphoma therapeutics.